Sterling Investment Counsel’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-5,893
Closed -$271K 148
2022
Q1
$271K Buy
5,893
+801
+16% +$38.2K 0.18% 116
2021
Q4
$312K Buy
+5,092
New +$352K 0.21% 104

Other funds holding ARKG

Sterling Investment Counsel's ARKG Position: Q2 2022 in Review

Sterling Investment Counsel sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 5,893 shares — an estimated $271K sold.

Sterling Investment Counsel first reported a position in ARKG in Q4 2021 and held it in 2 quarters. The position peaked at $312K in Q4 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

  • Sterling Investment Counsel reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
  • Sterling Investment Counsel sold 5,893 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $271K.
  • Sterling Investment Counsel first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 2 quarters.
  • Sterling Investment Counsel's ARK Genomic Revolution ETF position peaked at $312K in Q4 2021.
  • 333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Sterling Investment Counsel's 13F filing for Q2 2022, filed 18 Jul 2022.